MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.980
-0.060
-1.97%
Closed 16:00 04/03 EDT
OPEN
3.050
PREV CLOSE
3.040
HIGH
3.140
LOW
2.960
VOLUME
22.97K
TURNOVER
--
52 WEEK HIGH
6.05
52 WEEK LOW
2.317
MARKET CAP
68.81M
P/E (TTM)
-4.1309
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ORMP stock price target is 10.50 with a high estimate of 20.00 and a low estimate of 5.50.

EPS

ORMP News

More
  • Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
  • PR Newswire · 3d ago
  • NVAX, INSG among premarket gainers
  • Seeking Alpha - Article · 3d ago
  • Oramed CEO Sends Letter To Shareholders, Highlights Oral Insulin FDA End-Of-Phase 2 Meeting, NASH Intermediate Study Data Expected This Qtr., Co. Has ~$50M In Cash
  • Benzinga · 3d ago
  • Does Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Have A Particularly Volatile Share Price?
  • Simply Wall St. · 5d ago

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About ORMP

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
More

Webull offers kinds of Oramed Pharmaceuticals, Inc. stock information, including NASDAQ:ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions.